CD79A and schizophrenia: A large study of 1401 schizophrenia patients from the CATIE study (clinical Antipsychotic Trials of Intervention Effectiveness), and 900 controls, revealed that 23.1% of patients had moderate-to-high levels of IgA to gliadin (IgA-AGA) compared with 3.1% in the control group (84).